Mayo Clinic (Jacksonville)
Jacksonville, FL
Filters
Save & Share
Clear Filters
Diagnosis
Treatment History
BCMA Therapy
This stands for B Cell Maturation Antigen (BCMA) and includes treatments such as ide-cel, cilta-cel or belantamab mafodotin.
Not currently accepting
EXCALIBER-Maintenance
Phase 3 Clinical Trial Comparing Iberdomide VS Lenalidomide as Maintenance Therapy Following Autologous Stem Cell Transplant in Participants with Newly Diagnosed Multiple Myeloma
Learn more- CELMoD
- Randomization
- Phase 3
Not yet accepting
CA088-1005
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
Learn more- CAR T Cell
- CELMoD
- GPRC5D
- Phase 1
Accepting patients
CAMMA-2
A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma (CAMMA 2)
Learn more- Bispecific Antibody
- FCRH5
- Phase 1/2
Accepting patients
DREAMM12
A Study of Belantamab Mafodotin (GSK2857916) in Multiple Myeloma Participants With Normal and Varying Degrees of Impaired Renal Function
Learn more- Antibody Drug Conjugate (ADC)
- BCMA
- Phase 1
Not yet accepting
GCO12F CAR-T
A Phase 1b/2 Study of GC012F, a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Relapsed/Refractory Multiple Myeloma
Learn more- CAR T Cell
- BCMA
- CD19
- Phase 1/2
Accepting patients
Different Doses of Belantamab Mafodotin
Phase II Trial for Evaluation of Alternate Doses and Dosing Schedules of Belantamab Mafodotin in Triple-Class Refractory Multiple Myeloma
Learn more- Antibody Drug Conjugate (ADC)
- BCMA
- Randomization
- Phase 2
Accepting patients
Triplet Induction + 1 or 2-Drug Maintenance
A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance
Learn more- Monoclonal Antibody
- CD38
- Maintenance
- Randomization
- Phase 3
Accepting patients
APG-2575
APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
Learn more- BCL-2 Inhibitor
- Phase 1/2
- Has results
Accepting patients
APG-2575
APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies
Learn more- BCL-2 Inhibitor
- Phase 1
Accepting patients
Cemsidomide (CFT7455)
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Learn more- Phase 1/2
2 hidden based on your filters. Show All